AHA News: Diabetes and Heart Failure Are Linked; Treatment Should Be Too

Title: AHA News: Diabetes and Heart Failure Are Linked; Treatment Should Be TooCategory: Health NewsCreated: 6/6/2019 12:00:00 AMLast Editorial Review: 6/7/2019 12:00:00 AM
Source: MedicineNet Diabetes General - Category: Endocrinology Source Type: news

Related Links:

In this study, compared to young mice (4 months of age), aged mice (20-22 months of age) exhibited increased left ventricular weight and cardiomyocyte volume, and showed reduction in cardiomyocyte number, together with reduced ventricular function, indicating the pathological roles of cardiomyocyte senescence in the aged heart. Heart failure can be characterized into two types depending on the level of systolic function. One is described as heart failure with reduced ejection fraction (HFrEF), another is classified as heart failure with preserved ejection fraction (HFpEF), and both types of heart failure are prevale...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
Data from recent cardiovascular outcome trials in patients with type 2 diabetes (T2D) suggest that sodium-glucose cotransporter 2 (SGLT2) inhibitors can prevent development of heart failure (HF) and prolong li...
Source: Trials - Category: General Medicine Authors: Tags: Study protocol Source Type: research
Nocturnal polyuria (NP), the most common etiology of nocturia, is a bothersome condition characterized by overproduction of urine at night.1,2 NP may result from abnormalities in the normal circadian variation in endogenous arginine vasopressin (AVP) secretion,3 and it can also be associated with various medical conditions, including congestive heart failure, diabetes mellitus, obstructive sleep apnea, peripheral edema, excessive night-time fluid intake, as well as “normal” aging.4 There is a strong need to manage this burdensome condition by identifying the causative factors and associated comorbidities.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
AbstractPurpose of the ReviewHyperactivity of sympathetic nervous system (SNS) plays a role in the development of arterial hypertension and heart failure, two co-morbidities frequently associated with type 2 diabetes (T2DM). This review aims at analyzing the effects of sodium-glucose cotransporter type 2 inhibitors (SGLT2is) on blood pressure and more especially on SNS activity in patients with T2DM.Recent FindingsBy enhancing glucosuria, natriuresis, and osmotic diuresis, SGLT2is improve glucose control, promote weight loss, lower arterial blood pressure, and reduce the risk of major cardiovascular events and hospitalizat...
Source: Current Cardiology Reports - Category: Cardiology Source Type: research
DiscussionThe Empire HF trial will elucidate the effects and modes of action of empagliflozin in HFrEF patients with and without T2D and provide important mechanistic data which will complement ongoing event-driven trials.Trial registrationClinicaltrialsregister.eu, EudraCT Number2017-001341-27. Registered on 29 May 2017.ClinicalTrials.gov,NCT03198585. Registered on 26 June 2017.
Source: Trials - Category: Research Source Type: clinical trials
Abstract The ECM (extracellular matrix) network plays a crucial role in cardiac homeostasis, not only by providing structural support, but also by facilitating force transmission, and by transducing key signals to cardiomyocytes, vascular cells, and interstitial cells. Changes in the profile and biochemistry of the ECM may be critically implicated in the pathogenesis of both heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. The patterns of molecular and biochemical ECM alterations in failing hearts are dependent on the type of underlying injury. Pressure overload trig...
Source: Circulation Research - Category: Cardiology Authors: Tags: Circ Res Source Type: research
Publication date: Available online 20 June 2019Source: American Heart JournalAuthor(s): Peter Czobor, Yun-Yi Hung, David Baer, Dana McGlothlin, Dana Weisshaar, Jonathan ZaroffAbstractBackgroundLight Chain (AL) and transthyretin (ATTR) amyloidosis are the most common forms of amyloid cardiomyopathy. Population based studies describing the epidemiology and clinical features of amyloid cardiomyopathy are often based in tertiary medical centers and thus may be limited by referral bias.Methods and Results.We performed a cohort study of 198 patients diagnosed and treated in the Kaiser Permanente Northern California health care s...
Source: American Heart Journal - Category: Cardiology Source Type: research
Conclusions: The mFI-5 is an independent predictor of postoperative morbidity and mortality in elderly patients undergoing surgery for hip fractures. This clinical tool can be used by hospitals and surgeons to identify high-risk patients, accurately council patients and families with transparency, and guide perioperative care to optimize patient outcomes. Level of Evidence: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.
Source: Journal of Orthopaedic Trauma - Category: Orthopaedics Tags: Original Article Source Type: research
ConclusionThe EMPERIAL ‐Preserved and EMPERIAL‐Reduced trials will determine the effects of empagliflozin on exercise capacity and patient‐reported outcomes in patients with HFpEF and HFrEF, respectively, and provide insight into the potential of empagliflozin in the treatment of patients with HF.Clinical Trial Registration:ClinicalTrials.gov ID: NCT03448406 (EMPERIAL ‐Preserved), NCT03448419 (EMPERIAL‐Reduced).
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Study Design Source Type: research
Doctors often ask their patients to follow specific instructions as part of their prescribed treatment and hope that they do so. However, physicians currently have few ways of tracking a patient’s compliance. They can only base their diagnoses and recommended course of action on what they observe and hear from the patient in the examination room. When patients are asked to share their own accounts of their health condition and treatment progress, their reports can be limited or incomplete – it’s only human nature. Instead, real-world data should supplement t...
Source: MDDI - Category: Medical Devices Authors: Tags: Digital Health Source Type: news
More News: Cardiology | Diabetes | Endocrinology | Heart | Heart Failure